Cover image for Vol. 9 Issue 4

Recently Published Issues

See all

Latest News

Browse more news


Follow ChemMedChem on Twitter

April 15, 2014

VIP: High-Throughput Screening of Metal–N-Heterocyclic Carbene Complexes against Biofilm Formation by Pathogenic Bacteria

VIP: High-Throughput Screening of Metal–N-Heterocyclic Carbene Complexes against Biofilm Formation by Pathogenic BacteriaThierry Bernardi,* Stéphanie Badel, Pascal Mayer, Jérome Groelly, Pierre de Frémont, Béatrice Jacques, Pierre Braunstein, Marie-Laure Teyssot, Christelle Gaulier, Federico Cisnetti, Arnaud Gautier,* Sylvain Roland*

The treatment of certain bacterial infections has become a major public health concern with the increasing emergence of pathogenic bacterial strains that are resistant to most available antibiotics. Alternative strategies to those involving conventional antibiotic treatments are urgently needed to treat these refractory infections. Read more...

Your Comment...

[Browse more news]

Recently Published Articles

  1. Design, Synthesis, and Activity Evaluation of GK/PPARγ Dual-Target-Directed Ligands as Hypoglycemic Agents

    Dr. Jianxun Lu, Lei Lei, Yi Huan, Yongqiang Li, Dr. Lijing Zhang, Zhufang Shen, Dr. Wenxiang Hu and Zhiqiang Feng

    Article first published online: 15 APR 2014 | DOI: 10.1002/cmdc.201400009

    Thumbnail image of graphical abstract

    Two birds, one stone: GK/PPARγ dual-target ligands were constructed by rational combination of pharmacophores from known GK activators and PPARγ agonists. Their ability to induce GK and PPARγ transcriptional activity were evaluated, and the putative binding modes of one of the most promising compounds were also explored by molecular docking simulations with GK and PPARγ.

  2. High-Throughput Screening of Metal-N-Heterocyclic Carbene Complexes against Biofilm Formation by Pathogenic Bacteria

    Dr. Thierry Bernardi, Stéphanie Badel, Dr. Pascal Mayer, Jérome Groelly, Dr. Pierre de Frémont, Dr. Béatrice Jacques, Dr. Pierre Braunstein, Dr. Marie-Laure Teyssot, Christelle Gaulier, Dr. Federico Cisnetti, Dr. Arnaud Gautier and Dr. Sylvain Roland

    Article first published online: 11 APR 2014 | DOI: 10.1002/cmdc.201402012

    Thumbnail image of graphical abstract

    Film screening: Metal-N-heterocyclic carbene (NHC) complexes of group 11 metals (Ag, Au, Cu) strongly inhibit biofilm formation by representative pathogenic bacteria at low concentrations. The highest and broadest activities are obtained with silver as the metal complexed with lipophilic NHCs. This opens new perspectives to develop alternative drugs to treat biofilm-associated pathogens.

  3. Caulerpenyne and Related Bis-enol Esters Are Novel-Type Inhibitors of Human 5-Lipoxygenase

    Phillipp Richter, Gregor Schubert, Anja Maria Schaible, Prof. Dr. Levent Cavas, Prof. Dr. Oliver Werz and Prof. Dr. Georg Pohnert

    Article first published online: 11 APR 2014 | DOI: 10.1002/cmdc.201402065

    Thumbnail image of graphical abstract

    Stripping down to the essentials: Synthetic analogues of the lipoxygenase inhibitor caulerpenyne were tested on their inhibitory effect on human lipoxygenases. Systematic evaluation revealed a novel mode of action compared to established lipoxygenases inhibitors as well as a substantially simplified synthetic inhibitor for human 5-lipoxygenase.

  4. Inhibition of Cathepsin Activity in a Cell-Based Assay by a Light-Activated Ruthenium Compound

    Dr. Tomasz Respondek, Rajgopal Sharma, Mackenzie K. Herroon, Dr. Robert N. Garner, Dr. Jessica D. Knoll, Eric Cueny, Prof. Claudia Turro, Dr. Izabela Podgorski and Prof. Jeremy J. Kodanko

    Article first published online: 11 APR 2014 | DOI: 10.1002/cmdc.201400081

    Thumbnail image of graphical abstract

    Illuminating specificity: Photoactivated inhibitors provide spatial control over cysteine cathepsin activity. A nontoxic ruthenium complex was identified that releases a cathepsin K inhibitor, giving 35-fold enhancement over inhibition upon exposure to light. Light-activated inhibition of cathepsin activity was demonstrated in a cell-based assay with murine osteoclasts.

  5. The Discovery of Potent Nonstructural Protein 5A (NS5A) Inhibitors with a Unique Resistance Profile—Part 1

    Thien Duc Tran, Florian Wakenhut, Dr. Chris Pickford, Stephen Shaw, Dr. Mike Westby, Caroline Smith-Burchnell, Lesa Watson, Michael Paradowski, Dr. Jared Milbank, Dr. Rebecca A. Brimage, Rebecca Halstead, Dr. Rebecca Glen, Dr. Craig P. Wilson, Fiona Adam, Duncan Hay, Jean-Yves Chiva, Carly Nichols, Dr. David C. Blakemore, Iain Gardner, Satish Dayal, Dr. Andrew Pike, Rob Webster and Dr. David C. Pryde

    Article first published online: 11 APR 2014 | DOI: 10.1002/cmdc.201400045

    Thumbnail image of graphical abstract

    Resisting resistance: An investigation into the anti-hepatitis C virus (HCV) replicon activity of a series of biaryl-linked pyrrolidine NS5A inhibitors explored a diverse range of core structure modifications as key determinants of antiviral activity and susceptibility to common resistance mutations. Further evaluation of several core structure designs identified a compound with excellent pharmacokinetics, suitable for once daily dosing.